ROSEN, A RESPECTED AND LEADING FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE

Core Points - Rosen Law Firm is reminding purchasers of Skye Bioscience, Inc. securities of the January 16, 2026 lead plaintiff deadline for a class action lawsuit [1][2] - Investors who purchased Skye securities between November 4, 2024, and October 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4] Company Details - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [4] - The firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [3]